Eur J Biochem 270, 3891–3903 (2003) Ó FEBS 2003 doi:10.1046/j.1432-1033.2003.03771.x Arsenite stimulated glucose transport in 3T3-L1 adipocytes involves both Glut4 translocation and p38 MAPK activity Merlijn Bazuine, D Margriet Ouwens, Daan S Gomes de Mesquita and J Antonie Maassen Department of Molecular Cell Biology, Leiden University Medical Centre, Leiden, the Netherlands The protein-modifying agent arsenite stimulates glucose uptake in 3T3-L1 adipocytes In the current study we have analysed the signalling pathways that contribute to this response By subcellular fractionation we observed that arsenite, like insulin, induces translocation of the GLUT1 and GLUT4 glucose transporters from the low-density membrane fraction to the plasma membrane Arsenite did not activate early steps of the insulin receptor (IR)-signalling pathway and the response was insensitive to inhibition of phosphatidylinositol-3¢-kinase (PI-3¢) kinase by wortmannin These findings indicate that the ƠclassicalÕ IR–IR substrate–PI-3¢ kinase pathway, that is essential for insulin-induced GLUT4 translocation, is not activated by arsenite However, arsenite-treatment did induce tyrosinephosphorylation of c-Cbl Furthermore, treatment of the cells with the tyrosine kinase inhibitor, tyrphostin A25, abolished arsenite-induced glucose uptake, suggesting that the induction of a tyrosine kinase by arsenite is essential for glucose uptake Both arsenite and insulin-induced glucose uptake were inhibited partially by the p38 MAP kinase inhibitor, SB203580 This compound had no effect on the magnitude of translocation of glucose transporters indicating that the level of glucose transport is determined by additional factors Arsenite- and insulin-induced glucose uptake responded in a remarkably similar dose-dependent fashion to a range of pharmacological- and peptide-inhibitors for atypical PKC-k, a downstream target of PI-3¢ kinase signalling in insulin-induced glucose uptake These data show that in 3T3-L1 adipocytes both arsenite- and insulininduced signalling pathways project towards a similar cellular response, namely GLUT1 and GLUT4 translocation and glucose uptake This response to arsenite is not functionally linked to early steps of the IR–IRS–PI-3¢ kinase pathway, but does coincide with c-Cbl phosphorylation, basal levels of PKC-k activity and p38 MAPK activation Insulin induces multiple responses in target tissues such as adipocytes and muscle through the intracellular activation of several signal transduction pathways These responses include a pronounced anabolic action on protein and lipid metabolism, an antiapoptotic response, an increase in glucose uptake, and stimulation of glycogen synthesis [1,2] Insulin-stimulated glucose uptake occurs primarily via translocation of the GLUT4 glucose transporter to the plasma membrane [3,4] This process is initiated by the activation of the insulin receptor (IR) tyrosine kinase followed by receptor autophosphorylation and tyrosine phosphorylation of downstream effectors like insulin receptor substrate-1 (IRS-1), IRS-2 and related proteins Tyrosine phosphorylated IRS proteins provide docking sites for class I phosphatidylinositol-3¢ (PI-3¢) kinase that becomes activated upon binding to these proteins [5,6] Numerous studies have shown that PI-3¢ kinase activation provides an essential signal for the stimulation of glucose uptake by insulin [7,8] Downstream targets of PI-3¢ kinase in 3T3-L1 adipocytes that have been implicated in signalling towards GLUT4 translocation are the AGC kinase family members PDK1, PKB and the atypical PKC-k/-f [9–11], of which 3T3-L1 adipocytes only express the k-isoform [12] Recent data also demonstrate the involvement of an additional, nonPI-3¢ kinase dependent pathway involving c-Cbl which becomes tyrosine-phosphorylated upon APS (adapter protein with a PH and SH2 domain)-mediated association with the activated insulin receptor [13] Subsequently, tyrosine-phosphorylated c-Cbl translocates towards the caveolae and induces the activation of the small GTP-binding protein, TC10 [14], ultimately signalling towards the exocyst complex (Exo70) involved in GLUT4 translocation [15] Apart from insulin, some other stimuli, like muscle contraction, H2O2 and hyperosmotic shock, have been shown to stimulate GLUT4-mediated glucose uptake in adipocytes and muscle Most studies show that these stimuli are not sensitive to inhibition by wortmannin, indicating PI-3¢ kinase is not involved in glucose uptake mediated by these agents [16–18] Sodium arsenite is known for its atherogenic, carcinogenic and genotoxic effects Recently, arsenite has also Correspondence to J A Maassen, Department of Molecular Cell Biology, Leiden University Medical Centre, Wassenaarseweg 72, PO Box 9503, 2333 AL, Leiden, the Netherlands Fax: + 31 71 5276437, Tel.: + 31 71 5276127, E-mail: J.A.Maassen@lumc.nl Abbreviations: IR(s), insulin receptor (substrates); IBMX, 1-methyl3-isobutylxanthine; PI-3¢, phosphatidylinositol-3¢-kinase; 2-DOG, 2-deoxy-D[14C]glucose; BIM I, bisindolylmaleimide I; LDM, low density microsome; PM, plasma membrane; TPA, 12-O-tetradecanoylphorbol 13-acetate (Received 18 December 2002, revised 24 July 2003, accepted 28 July 2003) Keywords: PKC-k; PKB; PI-3¢ kinase; insulin; Cbl Ó FEBS 2003 3892 M Bazuine et al (Eur J Biochem 270) been used effectively as a chemotherapeutic drug in the treatment of acute promyelocytic leukaemia patients [19,20] At the protein level, arsenite exerts its biological effects through modification of vicinal sulfhydryl groups in specific target proteins For instance, arsenite specifically inactivates the E2 subunit of branched-chain alphaketo acid dehydrogenase (but not the other subunits) [21] and activates heat shock protein 70 [22] Arsenite is also a potent activator of the stress kinases, JNK and p38, by modulating the activity of an unidentified target protein [23] Furthermore, arsenite has been shown to induce glucose uptake in 3T3-L1 adipocytes, baby hamster kidney cells and L6 muscle cells [24–26] As the action of arsenite involves the modification of a limited number of arsenite-sensitive target proteins, we hypothesized that elucidation of the mechanism of arsenite-induced glucose uptake may contribute to a better understanding of insulin-induced glucose uptake In this study, we observed that arsenite displays insulinlike effects on GLUT4-mediated glucose transport in adipocytes To explore the underlying mechanism we analysed the signalling pathways that are activated by arsenite in comparison to insulin and that contribute to stimulation of glucose uptake Experimental procedures Materials Dulbecco’s modified Eagle’s medium (DMEM) was purchased from Life Technologies, Inc.; foetal bovine serum was from Brunschwig, Amsterdam; bovine insulin, 1-methyl-3-isobutylxanthine (IBMX), dexamethasone, 12-O-tetradecanoylphorbol 13-acetate (TPA) and 2-deoxyglucose were obtained from Sigma 2-deoxy-D-[14C]glucose was purchased from NEN-Dupont Tyrphostin A25, SB203580, chelerythrine chloride, bisindolylmaleimide I, Go 6976, Ro 31-8220 and Ro 32-0432 were from Calbioă chem LY-294002, microcystin LR and wortmannin were obtained from Alexis Myristoylated pseudosubstrate peptide inhibitors for PKC-a/-b and PKC-k/-f were purchased from Biomol For an overview of the characteristics of the pharmacological inhibitors applied in this study, see Table Antibodies Polyclonal antisera recognizing IRS-1, and the regulatory subunit of PI-3¢ kinase were described previously [27] Table Characteristics of pharmacological inhibitors applied in this study Pharmacological inhibitor Concentration applied Described target IC50 Reference Bisindolyl-maleimide I lM Chelerythrine Chloride 10 lM Go 6976 ă 100 nM LY 294002 10 lM Ro31–8220 0–20 lM PKC-a, bI, bII, c, d, e 5-hydroxytryptamine3 receptor Glycogen synthase kinase 3b K(ACh)channels MAPK activated protein-kinase 1b p70 S6 kinase Mitogen and stress activated kinase-1 AMP-activated protein kinase Phosphorylase kinase PKC K(ACh) channels Trk A and B Conventional PKC-a Conventional PKC-bI PKC-l (PRK) Phosphatidylinositol 3¢-kinase Casein kinase Conventional and novel PKC Atypical PKC-k Atypical PKC-f 10–100 nM nM 170 nM 100 nM 50 nM 100 nM 95% of cells displayed adipocyte morphology being used Prior to use, adipocytes were serum starved for 16 h with DMEM supplemented with 0.5% foetal bovine serum Membrane isolation assay 3T3-L1 adipocytes were stimulated as indicated in the figure legends Subsequently cells were washed twice in ice-cold HES buffer (20 mM Hepes pH 7.4, mM EDTA and 250 mM sucrose) on ice and scraped in HES buffer in the presence of protease inhibitors (complete protease inhibitor cocktail, Boehringer Mannheim) Samples were homogenized by nine times three strokes in a glass potter homogenizer after which low density microsome (LDM) and plasma membrane (PM) fractions were isolated by differential centrifugation as described by Simpson et al [31] Equal amounts of protein as determined with BCA protein assay reagent (Pierce) were subjected to immunoblot analysis using various antibodies Plasma membrane-lawn assay The plasma membrane-lawn assay was performed as described previously [32] Digital fluorescence imaging was performed using a Leica DM-RXA epifluorescence microscope (Leica, Germany) equipped with a 100-W mercury lamp and the appropriate filters Assay of 2-deoxyglucose uptake 3T3-L1 adipocytes, grown in 12-well plates (Costar), were subjected to an assay of 2-deoxy-D-[14C]glucose (0.075 lCi per well) uptake as described previously [33] Arsenite induced glucose-uptake (Eur J Biochem 270) 3893 Immunoprecipitations and Western blotting Dishes (9 cm) of 3T3-L1 adipocytes were stimulated with agonists Immunoprecipitation and immunoblotting procedures were as described previously [27] For c-Cbl immunoprecipitation 9-cm dishes of 3T3-L1 adipocytes were stimulated with agonists and scraped in lysis buffer (1 mM Na3VO4, mM EGTA, mM EDTA, 50 mM Tris/HCl pH 7.4, 1% NP-40, 0.5% sodium deoxycholate, 150 mM NaCl, mM NaF in the presence of protease inhibitors) Cell lysates were tumbled for half an hour at °C, cell lysate was cleared from cellular debris by spinning at 14 000 g, for 10 at °C in a table-top centrifuge About mg of cell lysate was subjected to immunoprecipitation using lg of anti-Cbl mouse monoclonal 7G10 (UBI) for 1.5 h at °C Immunocomplexes were harvested by incubating with ProtG beads for 1.5 h at °C Beads were washed in lysis buffer and dissolved subsequently in sample buffer Phosphotyrosine was demonstrated by immunoblotting using anti-pY20 followed by anti-(mouse HRP) secondary Ig Immunoblots were quantified using LUMIANALYST software on a LumiImager (BoehringerMannheim) PI-3¢ kinase activity assay Dishes (9 cm) of 3T3-L1 adipocytes were stimulated with agonists and immunoprecipitated using time, concentration and antibodies as indicated in the figure legends Cells were lysed and IRS-1 and p85 immunoprecipitates collected on protein A–Sepharose beads were analysed for the coprecipitation of in vitro PI-3¢ kinase activity using lCi c-32Plabelled ATP per reaction as described by Burgering et al [34] Incorporated radioactivity was quantified on a Molecular Dynamics phosphorimager PKC-k kinase assay Dishes (9 cm) of 3T3-L1 adipocytes were stimulated with 100 nM of insulin for 10 or 0.5 mM arsenite for 30 Cells were lysed in an NP-40 based lysis buffer (see above) in the presence of lM microcystin LR and immunoprecipitated with lg mouse monoclonal PKC-k for 1.5 h at °C Subsequently, Prot-G beads were added and complexes were harvested after another 1.5 h The precipitate was washed three times with lysis buffer and two times with kinase assay buffer (100 mM Hepes pH 7.4, 10 mM MgCl2, mM dithiothreitol) PtdSer (4 lg per sample) was dried under N2(g) and dissolved in 25 lL kinase buffer per sample Subsequently, PtdSer was waterbath-sonicated three times for and 25 lL sample kinase buffer, ATP (40 lM, final concentration), lCi c-32P-labelled ATP per reaction, dithiothreitol (1.5 mM), PKI (1 mM), the indicated concentrations of Ro 31-8220, and PKCe-substrate (40 lM) were added As a control, 10 lM of a peptide identical to the PKC-k pseudosubstrate domain was added to determine the specificity of the assay Kinase reactions were allowed to proceed for 10 at 37 °C under gentle agitation Twenty microlitres of each reaction was spotted on p81 paper and washed three times for with 0.85% (v/v) phosphoric acid, and once for with acetone P81 papers were air dried and analysed in a scintillation counter 3894 M Bazuine et al (Eur J Biochem 270) Ó FEBS 2003 Statistical analyses Data were analysed with an independent-samples t-test using SPSS 10.0 Curves represent fits to data by nonlinear regression analysis using GRAPHPAD PRISM 2.01 Results Arsenite induces 2-DOG uptake, GLUT1 and GLUT4 translocation in 3T3-L1 adipocytes Incubation of 3T3-L1 adipocytes with arsenite stimulated the uptake of hexose in a time- and dose-dependent manner Stimulation of 2-deoxy-D[14C]glucose (2-DOG) uptake was maximal at a 30-min preincubation period with 0.5 mM arsenite (Fig 1A,B) On average, maximal stimulation of glucose uptake was approximately sevenfold for insulin and threefold for arsenite When insulin was added to adipocytes during the final 15 minutes of a 30-min incubation with arsenite, no significant additive response was seen on arsenite-induced glucose uptake (Fig 1C) Under these conditions, insulin did induce tyrosine phosphorylation of IRb, IRS-1 and IRS-2, indicating that arsenite does not interfere with the insulin-induced activation of this pathway (data not shown) Insulin-stimulated glucose transport predominantly involves GLUT4 translocation from an intracellular microsomal compartment to the plasma membrane of adipocytes along with some induction of GLUT1 translocation To determine whether arsenite stimulates GLUT1 and GLUT4 translocation, we fractionated adipocytes into membrane (PM) and microsomal vesicle (LDM) fractions Equal amounts of protein ( 10 lg) were subjected to immunoblot analysis (Fig 2A,C) Plasma membrane fractions were identified using antibodies against the IR b-chain and integrin-b1 (data not shown) As can be seen in Fig 2A, when probing the fractions with an antibody against GLUT4, both insulinand arsenite-treatment resulted in a shift of GLUT4 from the microsomal fractions towards the plasma membrane fractions Figure 2C shows that insulin induces some translocation of GLUT1 towards the plasma membrane, as did arsenite, albeit at lower levels than insulin The amounts of GLUT1 and GLUT4 in each fraction were quantified and expressed as a relative amount of total GLUT protein in these fractions Arsenite significantly increases the amount of GLUT4 in the PM (Fig 2B), albeit at a lower level than insulin With respect to GLUT1, although a consistent increase in the amount of GLUT1 translocating towards the plasma membrane was observed this did not reach significant levels compared to basal levels of GLUT1 in the PM (Fig 2D) Furthermore, arsenite did not change the total amount of GLUT4 or GLUT1 in 3T3-L1 adipocytes (data not shown) It should be noted that both GLUT1 and GLUT4 are heavily glycosylated and show heterogeneous mobility An alternative method to investigate GLUT protein translocation is the plasma-lawn assay In this analysis, sonicated cells are probed with an antibody recognizing GLUT1 or GLUT4 and subjected to immunofluorescnce microscopy As can be seen in Fig 2E, both GLUT1 and GLUT4 are present in PM-lawns at higher quantities Fig Arsenite induces glucose uptake in 3T3-L1 adipocytes in a doseand time-dependent manner (A) 3T3-L1 adipocytes were stimulated with the indicated concentrations of arsenite for 30 and assayed for 2-deoxy-D[14C]glucose (2-DOG) uptake (B) 3T3-L1 adipocytes were stimulated with 0.5 mM arsenite for the indicated times and assayed for 2-DOG uptake (C) 3T3-L1 adipocytes were stimulated as indicated with 100 nM insulin for 15 (ins), 0.5 mM arsenite for 30 (as), or 0.5 mM arsenite for 30 combined with 100 nM insulin added after 15 (as/ins) and assayed for 2-DOG uptake Incorporated radioactivity was determined by liquid scintillation counting Values are mean ± SEM of at least four determinations; *P < 0.05 compared to basal and P < 0.05 for as/ins compared to ins after arsenite treatment as compared to the unstimulated situation Combined, these data indicate that arsenite-stimulated glucose uptake involves translocation of the GLUT1 and the insulin-responsive GLUT4 glucose transporter The effect of arsenite on early events in insulin receptor signalling To elucidate the signalling-pathways that contribute to arsenite-induced GLUT4 translocation, we examined Ó FEBS 2003 Arsenite induced glucose-uptake (Eur J Biochem 270) 3895 Fig Arsenite-treatment induces GLUT1 and GLUT4 translocation to the plasma membrane in 3T3-L1 adipocytes 3T3-L1 adipocytes were mocktreated (basal), stimulated for 15 with 100 nM insulin (insulin/ins) or for 30 with 0.5 mM arsenite (arsenite/as) (A) Adipocytes were fractionated and equal amounts of protein from both microsomal (LDM) and plasma membranes (PM) were analysed by immunoblot with antiGLUT4 Igs (B) GLUT4 levels in each fraction subjected to immunoblot analysis as in A were quantified using a LumiImager and expressed as a fraction of GLUT4 residing in either LDM or PM (C) Subcellular fractions as in (A) were also subjected to immunoblot analysis using antibodies against GLUT1 (D) GLUT1 levels in each fraction were quantified as in (B) and expressed as a fraction of GLUT1 residing in either LDM or PM The total amount of GLUT1 or GLUT4 in the HDM fraction did not alter during either arsenite- or insulin-treatment Data are expressed as mean ± SEM of at least three independent observations, *P < 0.05 compared to basal (E) 3T3-L1 adipocytes were mock-treated (none), stimulated for 15 with 100 nM insulin (ins) or for 30 with 0.5 mM arsenite (as) Adipocytes were subjected to PM-lawn analysis using antibodies against either GLUT1 or GLUT4 Data shown are a representative example of five independent observations for each condition whether arsenite activates intermediates of the insulin signalling-pathway Following stimulation of 3T3-L1 adipocytes with either insulin or arsenite, IR, IRS-1 and IRS-2 were immunoprecipitated and assessed for tyrosine phosphorylation by Western blotting As shown in Fig 3A–C, no significant increase in tyrosine phosphorylation of either IRb, IRS-1 or IRS-2 could be detected in response to arsenite Under these conditions, stimulation with insulin led to a pronounced tyrosine phosphorylation of these proteins In agreement with the lack of IRS-tyrosine phosphorylation in response to arsenite, no association of the p85 or p110a subunits of PI-3¢ kinase with the IRS proteins was detected, again in contrast to the situation seen after insulin stimulation (Fig 3B) Treatment with arsenite did not lead to phosphorylation of PKB on either Ser473 or Thr308, nor of phosphorylation of PKC-k on T403 This observation agrees with the absence of PI-3¢ kinase activation by arsenite in vivo (Fig 3D) Consistent with these observations, no increase of in vitro PI-3¢ kinase activity was observed in IRS-1 immunoprecipitates after arsenite treatment (Fig 4A), nor did we find any arsenite-induced stimulation of in vitro PI-3¢ kinase activity in immunoprecipitates of PI-3¢ kinase (Fig 4B) To investigate the possibility that basal PI-3¢ kinase activity in combination with arsenite-induced signals is needed to stimulate glucose uptake, we examined the effect of the PI-3¢ kinase inhibitor, wortmannin, on arseniteinduced glucose uptake Using concentrations that fully inhibited insulin-induced glucose uptake, arsenite-induced glucose uptake was unaffected by wortmannin (Fig 4C) Similar data were obtained using LY-294002 (data not shown) These observations suggest that arsenite-induced glucose uptake occurs without the need for PI-3¢ kinase activity, a situation that is in marked contrast to insulin induced glucose uptake Another early target of insulin action, the activation of ERK-1, -2 was also not activated appreciably in response to arsenite-treatment either (Fig 3D) The effect of arsenite on Cbl and caveolin-1 tyrosine phosphorylation A recently described PI-3¢ kinase independent pathway involved in insulin-induced glucose uptake in 3T3-L1 adipocytes involves Tyr phosphorylation of c-Cbl and caveolin-1 mediated by the IR Remarkably, we found 3896 M Bazuine et al (Eur J Biochem 270) Ó FEBS 2003 Fig The effect of arsenite on the activation status of early steps in insulin-responsive signal-transduction pathways 3T3-L1 adipocytes were stimulated as indicated with 100 nM insulin for or 0.5 mM arsenite for 30 Cell lysates were immunoprecipitated with anti-IR (A), anti-IRS-1 (B), anti-IRS-2 (C) followed by immunoblot analysis with anti-phosphotyrosine (ap-Tyr), anti-PI-3¢ kinase regulatory subunit (ap85) or anti-PI-3¢ kinase catalytic subunit (ap110a) as indicated Equal loading was confirmed using the respective antibodies used for immunoprecipitation (D) Total cell lysate of adipocytes (10 lg) stimulated as described above was analysed by immunoblot using phosphospecific antibodies against T202/Y204 of ERK-1/2 (apERK), T308 and S473 of PKB (apThr308 and apSer473), T403 of PKC-k (apPKCk) or PKB (aPKB) as indicated that arsenite did induce tyrosine-phosphorylation of both c-Cbl (Fig 5B) and caveolin-1 (Fig 5A), in spite of the absence of IR activation This observation suggests that arsenite does induce an as of yet unidentified tyrosine kinase activity in 3T3-L1 adipocytes To evaluate whether this tyrosine kinase activity is required for arsenite-induced glucose uptake, we applied the tyrosine kinase inhibitor, tyrphostin A25 Insulin-induced IRS and caveolin-1 tyrosine phosphorylation are attenuated, but still present after pretreatment with tyrphostin A25 (Fig 5A) Insulininduced Cbl phosphorylation is even enhanced by tyrphostin (Fig 5B) In contrast, arsenite-induced Cbl and caveolin-1 phosphorylation are strongly inhibited (Fig 5A,B) In a glucose uptake assay, tyrphostin A25 attenuated insulin-induced glucose uptake, but completely blocked arsenite-induced glucose uptake (Fig 5C) These data illustrate the distinct nature of the insulin- (namely the IR) and arsenite-induced tyrosine kinases, and furthermore they suggest that tyrosine kinase activity is a requirement for arsenite-mediated induction of glucose uptake in 3T3-L1 adipocytes The effect of the p38 MAPK inhibitor, SB203580, on arsenite-induced glucose uptake SB203580 is a pharmacological inhibitor of the MAP kinase family member p38 and has been shown to inhibit insulin induced glucose uptake by 3T3-L1 adipocytes and L6 muscle cells [35,36] Arsenite-treatment induced p38-phosphorylation on Thr180 and Tyr182, and phosphorylation of Fig Arsenite-induced in vitro PI-3¢ kinase activity 3T3-L1 adipocytes were stimulated as indicated with 100 nM insulin for or 0.5 mM arsenite for 30 Cell lysates were incubated for h with polyclonal antiserum against IRS-1 (A), or against the 85-kDa regulatory subunit of PI-3¢ kinase (B) Immunoprecipitates were washed and subsequently subjected to an in vitro PI-3¢ kinase assay Coprecipitating PI-3¢ kinase activity was determined on a phosphorimager as the relative stimulation of [c-32P]ATP incorporation into phosphatidylinositol standardized against untreated cells Data are expressed as the mean ± SEM of three observations, statistically significant compared to basal (*P < 0.05) (C) 3T3-L1 adipocytes were pretreated for 15 with 100 nM wortmannin Subsequently, adipocytes were mock-treated (basal) or stimulated as indicated with 100 nM insulin for 15 or with 0.5 mM arsenite for 30 in the continued presence of the pharmacological inhibitor and assayed for 2-DOG uptake Data are expressed as mean ± SEM of at least six observations Statistically significant data when compared to the samples not treated with wortmannin are indicated (*P < 0.05) MAPKAP-K2 on Thr334 (a direct target site of p38 MAP kinase activity [37]) Treatment with 10 lM SB203580 significantly inhibited arsenite-induced glucose uptake as well as MAPKAP-K2 and p38-phosphorylation (Fig 6A,B) In insulin-signalling, p38 MAPK has been implied in enhancing the intrinsic activity of the GLUT4 glucose transporter Thus, SB203580 has been shown to reduce insulin-induced glucose uptake without an effect on insulininduced GLUT4 translocation [35] SB203580 had a similar Ó FEBS 2003 Arsenite induced glucose-uptake (Eur J Biochem 270) 3897 The effect of pharmacological inhibitors of PKC-isoforms on arsenite-induced glucose uptake Atypical PKC isoforms (PKC lambda and zeta) have been implicated in insulin induced glucose uptake in adipocytes [11,12] We compared the effect of a number of pharmacological inhibitors for various PKC isoforms on arsenite- and insulin-induced glucose uptake in 3T3-L1 adipocytes Ro 318220 inhibited insulin- and arsenite-induced glucose uptake with similar dose–response relations More precisely, an IC50 value of approximately lM was found for the inhibition of insulin- and arsenite-induced glucose (Fig 7A) When PKC-k was purified by immunoprecipitation and subjected to an in vitro kinase assay, a similar dose dependency for the inhibition of PKC-k (an IC50 of lM) was observed (Fig 7B) Co-incubation with 50 lM of a peptide resembling the PKC-k pseudosubstrate domain reduced 32P incorporation by 90%, demonstrating the specificity of the assay In support of the data presented in Fig 3D, arsenite did not induce PKC-k activation over basal levels Hence, arsenite appears to require basal levels of PKC-k in conjunction with other signals to induce glucose uptake In addition the PKC-inhibitors, chelerythrine chloride, Ro 32-0432, bisindolylmaleimide I (BIM I) and Go 6976 ă were studied at concentrations well above the IC50 values for their respective conventional and novel PKC target proteins (Table 1) All inhibitors reduced TPA-induced ERK phosphorylation in 3T3-L1 adipocytes, demonstrating their functional interference with PKC (Fig 7C) Their effects on arsenite- and insulin-induced glucose uptake were minimal (Fig 7D) (although BIM I had a small but significant inhibitory effect), demonstrating that neither conventional nor novel PKC isoforms are involved in arsenite- or insulin-induced glucose uptake Fig The involvement of tyrosine kinase activity in arsenite-induced glucose uptake 3T3-L1 adipocytes were pretreated with for 15 with 25 lM tyrphostin A25 as indicated Subsequently, adipocytes were mock-treated (-), stimulated for with 100 nM insulin (INS) or for 30 with 0.5 mM arsenite (As) in the continued presence of the pharmacological inhibitor (A) Total cell lysate (10 lg) was subjected to immunoblot analysis using antibodies against phosphoY14 of caveolin-1 (ap-Cav1), phosphotyrosine (ap-Tyr) (shown are the IRSbands at 180 kDa) and IRS-1 (aIRS) for equal loading (B) 3T3-L1 adipocytes treated as described above were immunoprecipitated using antibodies against c-Cbl followed by immunoblot analysis using antibodies against phosphotyrosine (ap-Tyr) or Cbl (ac-Cbl) (C) 3T3L1 adipocytes were pretreated for 15 with 25 lM tyrphostin A25 Subsequently, adipocytes were mock-treated (basal), stimulated for 15 with 100 nM insulin or for 30 with 0.5 mM arsenite in the continued presence of the pharmacological inhibitor and assayed for 2-DOG uptake Data are expressed as mean ± SEM of at least six observations Statistically significant (*P < 0.05) when compared to the samples not treated with tyrphostin Statistically significant (P < 0.05) when compared to the basal (or arsenite) samples treated with tyrphostin A25 effect on arsenite-induced glucose uptake (Fig 6; compare A with C,D) i.e a reduction in glucose uptake without a reduction in GLUT4 translocation The effect of myristoylated PKC-k/-f and PKC-a/-b pseudosubstrate peptides on arsenite-induced glucose uptake To substantiate the observations made using Ro 31-8220 we investigated the effect of myristoylated peptide-inhibitors for PKC [11] on insulin- and arsenite-induced glucose uptake As can be seen in Fig 8B, a myristoylated peptide with a sequence similar to the pseudosubstrate domain of the atypical PKCs was capable of inhibiting insulin- as well as arsenite-induced glucose uptake A peptide resembling the pseudosubstrate domain of conventional PKC-a/-b had no significant inhibitory effect on either insulin- or arsenite induced glucose uptake (Fig 8B), whereas it did block TPA induced ERK phosphorylation demonstrating its functionality (Fig 8A) These observations corroborate the observations made with Ro 31-8220 Discussion Insulin-induced glucose uptake by adipocytes is determined by multiple factors, including: the translocation of glucose transporters from intracellular sites to the plasma membrane, expression levels of individual members of the glucose transporter family and by modulating the intrinsic activity (or, degree of occlusion) of glucose transporters (Fig 9) 3898 M Bazuine et al (Eur J Biochem 270) Ó FEBS 2003 Fig The effect of the p38 MAP kinase inhibitor, SB203580, on arsenite-induced glucose uptake and translocation of GLUT4 3T3-L1 adipocytes were pretreated for 30 with 10 lM SB203580 (A–D) Subsequently adipocytes were mock-treated (basal) or stimulated as indicated with 100 nM insulin for 15 (insulin) or with 0.5 mM arsenite for 30 (arsenite) in the continued presence of the pharmacological inhibitor and assayed for 2-DOG uptake (A) Data are expressed as the mean value ± SEM of at least six observations Statistically significant (*P < 0.05) when compared to samples without SB203580 (B) 3T3-L1 adipocytes were lysed and subjected to immunoblot analysis using antibodies against p38 MAPK (p38), phospho-specific antibodies against p38 (p-p38) and MAPKAP-K2 (p-MAPKAP-K2) (C) 3T3-L1 adipocytes treated as described above were subjected to cell fractionation and the effect of SB203580 on GLUT4 translocation was determined by immunoblotting followed by quantification in a lumni-imager as described for Fig 2B Samples pretreated with SB203580 are indicated with SB Data are expressed as the mean ± SEM of three independent experiments (D) Representative immunoblot probed with anti-GLUT4 Igs, used to obtain the data described in C Arsenite is a protein modifying agent known to react with sulfhydryl groups in a discrete number of proteins As a result these proteins are modified in their function and this can couple back to altered activity of signal transduction pathways In this report we demonstrate that arsenite displays insulin-mimicking effects in 3T3-L1 adipocytes: thus, arsenite stimulates 2-DOG uptake and induces translocation of the insulin-responsive GLUT4 glucose transporter from the low-density microsomal fraction towards the plasma membrane Comparable to other stress-inducing agents [38,39] arsenite acutely blocks insulin-induced glucose uptake (Fig 1C), however, and in contrast to oxidative and osmotic stress, arsenite did not interfere with early events in insulin-induced signalling A normal level of phosphorylation of IRS-1,2 and PKB was observed by insulininduction after incubation with arsenite (data not shown) Whereas PI-3¢ kinase activity is pivotal for insulininduced GLUT4 translocation, arsenite increases the uptake of 2-DOG without the need for PI-3¢ kinase activity as judged from the absence of an effect of arsenite on PI-3¢ kinase activation and the lack of inhibition by either wortmannin or LY 294002 Furthermore, arsenite does not activate other signalling steps normally activated in response to insulin, such as IR tyrosine kinase, IRS-1 and IRS-2 tyrosine phosphorylation, phosphorylation of PKC-k on T403 or phosphorylation of PKB on either Ser473 or Thr308 These observations suggest that the target of arsenite action resides downstream of PI-3¢ kinase or in a separate pathway A PI-3¢ kinase-independent pathway in insulin-induced GLUT4 translocation has recently been identified and involves tyrosine phosphorylation on several residues of the proto-oncogene c-Cbl [13,40] and caveolin-1 [41] by the activated insulin receptor Arsenite also induces c-Cbl and caveolin-1 tyrosine phosphorylation in 3T3-L1 adipocytes, however, given that arsenite does not activate the insulin receptor (Fig 3A) the two processes are mechanistically different The distinct nature of the insulin- and arsenite-induced tyrosine kinase activities is illustrated by the effects of tyrphostin A25 Whereas insulin-induced tyrosine kinase activity was attenuated (and Cbl-tyrosine phosphorylation levels even potentiated), all arseniteinduced tyrosine phosphorylation was strongly reduced The effects of tyrphostin A25 on insulin- and arseniteinduced glucose uptake mirrored these observations, i.e., insulin-induced glucose uptake was attenuated whereas arsenite-induced glucose uptake was lost These data also demonstrate that a tyrosine kinase activity is apparently required for the induction of glucose uptake by arsenite, Ó FEBS 2003 Arsenite induced glucose-uptake (Eur J Biochem 270) 3899 Fig The effect of PKC-inhibitors on arsenite-induced glucose uptake 3T3-L1 adipocytes were incubated with the indicated concentrations of Ro 31-8220 for 30 prior to stimulation Subsequently, adipocytes were mock-treated (basal), stimulated with 100 nM insulin for 15 (insulin) or 0.5 mM arsenite for 30 (arsenite) in the continued presence of Ro 31-8220 (A) 2-DOG uptake was assayed and data are expressed as mean ± SEM of two independent experiments each performed in triplicate (B) In vitro kinase assay performed in the continued presence of Ro 31-8220 Incorporated counts (in k c.p.m.) are expressed as mean ± SEM of two independent experiments each performed in duplicate (C,D) 3T3-L1 adipocytes were pretreated for 30 with 0.1 lM Go 6976, lM bisindolylmaleimide I (BIM I), 10 lM chelerythrine chloride (Chelă erythrine), or 10 lM Ro 320432 as indicated Subsequently, 3T3-L1 adipocytes were stimulated with 100 nM TPA for 15 and analysed for ERK-1/2 phosphorylation (C) 2-DOG uptake was tested in a separate experiment (D) After pretreatment with the indicated pharmacological inhibitors, adipocytes were mock-treated (basal), stimulated with 100 nM insulin for 15 (insulin), or 0.5 mM arsenite for 30 (arsenite) in the continued presence of the inhibitors 2-DOG uptake was assayed and data are expressed as mean ± SEM of at least two independent experiments each performed in triplicate, statistically significant compared to the uninhibited samples (*P < 0.05) as is the case for insulin The identity of the tyrosinekinase activity activated in response to arsenite remains to be resolved The pharmacological p38 MAPK inhibitor, SB203580, affects insulin-induced glucose transport by affecting intrinsic GLUT4 activity [35,36] Our results with this inhibitor confirmed this observation Furthermore, we demonstrate a similar effect on arsenite-induced glucose uptake Pre-treatment with 10 lM SB203580 had no effect on GLUT4 (or GLUT1) translocation but did reduce arsenite-induced glucose uptake by  30% Thus, our data show a similar contribution of p38-MAPK activity in combination with GLUT4 translocation in insulin- and arsenite-induced glucose uptake at the level of modulating the GLUT4 mediated transport activity Though we cannot fully exclude a similar effect of SB203580 on GLUT1 as well, this seems unlikely given that SB203850 had no effect whatsoever on arsenite- or insulin-induced glucose uptake levels in 3T3-L1 preadipocytes (expressing GLUT1 and no GLUT4) (data not shown) The term coined for the modulatory effect of SB203850 is Ôintrinsic activityÕ [35], possibly by altering the speed of transition between ÔoutwardÕ and ÔinwardÕ conformations of the transporter [42] The term ÔocclusionÕ has been used to describe a state in which the GLUT4 transporter is fully inserted to the plasma membrane, but incapable of binding and/or transporting glucose yet [43] This could be due to associating proteins blocking glucose transport, differences in LDM-derived and PM-membrane composition and/or a conformational change in the GLUT4transporter that is required for its activation If SB203580 hampers the progress through these stages, similar consequences are expected (i.e., GLUT4 being present in the plasma membrane, but less glucose being taken up) Arsenite-induced glucose uptake, which demonstrates a similar sensitivity to SB203580, may provide an additional tool for future research addressing these models Cellular stresses like hypoxia [44] and hyperosmolarity [45] increase glucose uptake through an upregulation of the amount of GLUT1 Arsenite in contrast, does not increase 3900 M Bazuine et al (Eur J Biochem 270) Fig Arsenite-induced glucose uptake is inhibited by a myristoylated PKC-k/-f, but not by PKC-a/-b pseudosubstrate peptide 3T3-L1 adipocytes were incubated with either myristoylated PKC-a/-b pseudosubstrate (myrPKC-a/b ps), or myristoylated PKC-k/–f pseudosubstrate (myrPKC-k/f ps) at the indicated concentrations for h prior to stimulation (A) 3T3-L1 adipocytes were treated with 100 nM TPA for 15 and subjected to immunoblotting as described in the legend of Fig 7C (B) 2-DOG uptake was tested in a separate experiment 3T3-L1 adipocytes were mock-treated (basal), stimulated for 15 with 100 nM insulin (insulin) or for 30 with 0.5 mM arsenite (arsenite) Data are expressed as mean ± SEM of at least two independent experiments each performed in triplicate, statistically significant compared to the uninhibited samples (*P < 0.05) the amount of GLUT1 Indeed, treatment of the adipocytes with the protein synthesis inhibitors cycloheximide or emetine had no effect on arsenite-induced glucose uptake (data not shown) Furthermore, the time-course of arseniteinduced glucose uptake, being maximal after 30 and declining thereafter (Fig 1B) already seems to argue against de novo synthesis of GLUT-transporters in mediating arsenite-induced glucose uptake Although most GLUT1 is already localized in the plasma membrane of an unstimulated adipocyte [46], some GLUT1 is known to cotranslocate with GLUT4 [47] and Fig C,D,E Moreover, treatment of 3T3-L1 adipocytes with TPA induced the specific translocation of GLUT1 and not GLUT4 towards the plasma membrane of 3T3-L1 adipocytes [48] Arsenite in contrast, induces the translocation of GLUT1 at about half the levels obtained with insulin Though failing to reach statistical significance (Fig 2D) this effect was consistently reproducible (e.g Fig 2C,E) Thus, clearly, arsenite differs from other types of cellular stress in that it projects towards a more insulin-like response (i.e., translocation of GLUT1 and 4) albeit at a lower level of efficiency When applying multiple pharmacological- and peptideinhibitors for several PKC isoforms we observed a common pattern of inhibition for insulin- and arsenite-induced Ó FEBS 2003 Fig A model highlighting the insulin- and arsenite-induced pathways to glucose uptake in 3T3-L1 adipocytes Our data suggest some common steps in both arsenite- and insulin-induced glucose uptake: activation of p38 MAPK and tyrosine-phosphorylation of c-Cbl In contrast to insulin, arsenite does not activate PI-3¢ kinase (and consequently does not activate PKC-k) However, the data suggests that basal levels of PKC-k activity are needed for arsenite-induced glucose uptake, as is indicated by the dashed arrow glucose uptake and similar concentration dependencies for the various agents Most notably, Ro 31-8220 inhibits both insulin- and arsenite-induced glucose uptake with an IC50 of lM suggesting an involvement of atypical PKCs The IC50 of atypical PKC for BIM I is 5.8 lM, hence the significant reduction in glucose uptake measured using lM (Fig 7D) fits with the observations made with Ro 31-8220 Inhibitors against conventional or novel PKCs such as Go 6976, ă chelerythrine chloride and Ro 32-0432 (a compound structurally related to Ro 31-8220) (Table 1) remained without effect, or acted even in a slightly potentiating manner Furthermore, both insulin- and arsenite induced glucose uptake was inhibited by treatment with a myristoylated PKC-k/f pseudosubstrate peptide, but not significantly sensitive to treatment with a PKC-a/b pseudosubstrate A formal exclusion of other intracellular targets with similar sensitivities to the inhibitors mentioned cannot, however, be excluded In the case of arsenite-induced glucose uptake, the myristoylated PKC-k/f pseudosubstrate peptide inhibited this response by approximately 50% (Fig 8B) Remarkably, when the effect of Ro 31-8220 on arsenite-induced GLUT4 translocation was determined a similar reduction in GLUT4 translocation was observed (data not shown) This is in contrast to the situation in response to insulin, where the inhibition is complete Another observation was that in contrast to insulin, arsenite did not induce T-loop phosphorylation of PKC-k (Fig 3D), nor did we observe an increase in the amount of incorporated radiolabelled phosphate in immunoprecipitated PKC-k (data not shown) Indeed, when analysing PKC-k activity in an in vitro kinase assay, no induction of PKC-k activity in response to arsenite was observed (Fig 7B) Thus, taken together, these data suggest that arsenite does not activate PKC-k, but does require the basal Ó FEBS 2003 activity of this enzyme (in conjunction with other signals) to induce GLUT-4 translocation in 3T3-L1 adipocytes Of note, the basal levels of PKC-k activity are already quite high, with only a 1.2 to 2-fold induction in response to insulin [9,11,12] (Fig 7B) These data are consistent with a common step in both insulin- and arsenite-induced glucose transport downstream of PI-3¢ kinase involving the activity of atypical PKC-isoforms, however, additional factors contribute to the level of arsenite-induced GLUT4 translocation and the magnitude of glucose uptake In summary, our data suggest a model as depicted in Fig 9, in which arsenite and insulin activate distinct signalling pathways that converge at several steps (e.g c-Cbl tyrosine phosphorylation, PKC-k activity and p38 MAPK activation) upstream of GLUT4 translocation and glucose uptake in 3T3-L1 adipocytes Acknowledgements We thank Drs Hans Joost and Annette Schurmann (Aachen and ă Potsdam, Germany) for their kind gift of antibodies against GLUT1 and and Dr Ken Siddle (Cambridge, UK) for antibodies against the insulin receptor We thank R van de Ven for excellent technical assistance with some of the glucose uptake experiments and valuable discussions We would also like to acknowledge Drs P J A van den Broek and J van der Zee for critical reading of this manuscript M B was supported by a grant from the Dutch Diabetes Foundation (DFN 98.106) References Combettes-Souverain, M & Issad, T (1998) Molecular basis of insulin action Diabetes Metab 24, 477–489 Miers, W.R & Barrett, E.J (1998) The role of insulin and other hormones in the regulation of amino acid and protein metabolism in humans J Basic Clin Physiol Pharmacol 9, 235–253 Stephens, J.M & Pilch, P.F (1995) The metabolic regulation and vesicular transport of GLUT4, the major insulin-responsive glucose transporter Endocr Rev 16, 529–546 Holman, G.D & Cushman, S.W (1994) Subcellular localization and trafficking of the GLUT4 glucose transporter isoform in insulin-responsive cells Bioessays 16, 753–759 Myers, M.G Jr & White, M.F (1993) The new elements of insulin signaling Insulin receptor substrate-1 and proteins with SH2 domains Diabetes 42, 643–650 White, M.F (1997) The insulin signalling system and the IRS proteins Diabetologia 40, S2–S17 Czech, M.P (1995) Molecular actions of insulin on glucose transport Annu Rev Nutr 15, 441–471 Hara, K., Yonezawa, K., Sakaue, H., Ando, A., Kotani, K., Kitamura, T., Kitamura, Y., Ueda, H., Stephens, L., Jackson, T.R., Hawkins, P.T., Dhand, R., Clark, A.E., Holman, G.D., Waterfield, M.D & Kasuga, M (1994) 1-phosphatidylinositol 3-kinase activity is required for insulin-stimulated glucose transport but not for RAS activation in CHO cells Proc Natl Acad Sci USA 91, 7415–7419 Vanhaesebroeck, B & Alessi, D.R (2000) The P13K-PDK1 connection: more than just a road to PKB Biochem J 346, 561–576 10 Burgering, B.M & Coffer, P.J (1995) Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction Nature 376, 599–602 11 Standaert, M.L., Galloway, L., Karnam, P., Bandyopadhyay, G., Moscat, J & Farese, R.V (1997) Protein kinase C-zeta as a downstream effector of phosphatidylinositol 3-kinase during Arsenite induced glucose-uptake (Eur J Biochem 270) 3901 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 insulin stimulation in rat adipocytes Potential role in glucose transport J Biol Chem 272, 30075–30082 Kotani, K., Ogawa, W., Matsumoto, M., Kitamura, T., Sakaue, H., Hino, Y., Miyake, K., Sano, W., Akimoto, K., Ohno, S & Kasuga, M (1998) Requirement of atypical protein kinase C lambda for insulin stimulation of glucose uptake but not for Akt activation in 3T3-L1 adipocytes Mol Cellular Biol 18, 6971– 6982 Liu, J., Kimura, A., Baumann, C.A & Saltiel, A.R (2002) APS facilitates c-Cbl tyrosine phosphorylation and GLUT4 translocation in response to insulin in 3T3-L1 adipocytes Mol Cellular Biol 22, 3599–3609 Chiang, S.H., Baumann, C.A., Kanzaki, M., Thurmond, D.C., Watson, R.T., Neudauer, C.L., Macara, I.G., Pessin, J.E & Saltiel, A.R (2001) Insulin-stimulated GLUT4 translocation requires the CAP-dependent activation of TC10 Nature 410, 944–948 Inoue, M., Chang, L., Hwang, J., Chiang, S.H & Saltiel, A.R (2003) The exocyst complex is required for targeting of Glut4 to the plasma membrane by insulin Nature 422, 629–633 Chen, D., Elmendorf, J.S., Olson, A.L., Li, X., Earp, H.S & Pessin, J.E (1997) Osmotic shock stimulates GLUT4 translocation in 3T3L1 adipocytes by a novel tyrosine kinase pathway J Biol Chem 272, 27401–27410 Barros, L.F., Marchant, R.B & Baldwin, S.A (1995) Dissection of stress-activated glucose transport from insulin-induced glucose transport in mammalian cells using wortmannin and ML-9 Biochem J 309, 731–736 Lund, S., Holman, G.D., Schmitz, O & Pedersen, O (1995) Contraction stimulates translocation of glucose transporter GLUT4 in skeletal muscle through a mechanism distinct from that of insulin Proc Natl Acad Sci USA 92, 5817–5821 Costantini, P., Jacotot, E., Decaudin, D & Kroemer, G (2000) Mitochondrion as a novel target of anticancer chemotherapy J Natl Cancer Inst 92, 1042–1053 Waxman, S & Anderson, K.C (2001) History of the development of arsenic derivatives in cancer therapy Oncologist 6, 3–10 Chuang, D.T., Hu, C.C., Ku, L.S., Niu, W.L., Myers, D.E & Cox, R.P (1984) Catalytic and structural properties of the dihydrolipoyl transacylase component of bovine branched-chain alpha-keto acid dehydrogenase J Biol Chem 259, 9277–9284 de La Serna, I.L., Carlson, K.A., Hill, D.A., Guidi, C.J., Stephenson, R.O., Sif, S., Kingston, R.E & Imbalzano, A.N (2000) Mammalian SWI-SNF complexes contribute to activation of the hsp70 gene Mol Cellular Biol 20, 2839–2851 Namgung, U & Xia, Z.G (2000) Arsenite-induced apoptosis in cortical neurons is mediated by c-Jun N-terminal protein kinase and p38 mitogen-activated protein kinase J Neuroscience 20, 6442–6451 Sviderskaya, E.V., Jazrawi, E., Baldwin, S.A., Widnell, C.C & Pasternak, C.A (1996) Cellular stress causes accumulation of the glucose transporter at the surface of cells independently of their insulin sensitivity J Membr Biol 149, 133–140 Widnell, C.C., Baldwin, S.A., Davies, A., Martin, S & Pasternak, C.A (1990) Cellular stress induces a redistribution of the glucose transporter FASEB J 4, 1634–1637 McDowell, H.E., Walker, T., Hajduch, E., Christie, G., Batty, I.H., Downes, C.P & Hundal, H.S (1997) Inositol phospholipid 3-kinase is activated by cellular stress but is not required for the stress-induced activation of glucose transport in L6 rat skeletal muscle cells Eur J Biochem 247, 306–313 Ouwens, D.M., van der Zon, G.C., Pronk, G.J., Bos, J.L., Moller, W., Cheatham, B., Kahn, C.R & Maassen, J.A (1994) A mutant insulin receptor induces formation of a Shc-growth factor receptor bound protein (Grb2) complex and p21ras–GTP without detectable interaction of insulin receptor substrate (IRS1) with 3902 M Bazuine et al (Eur J Biochem 270) 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 Grb2 Evidence for IRS1-independent p21ras-GTP formation J Biol Chem 269, 33116–33122 Telting, D., van der Zon, G.C., Dorrestijn, J & Maassen, J.A (2001) IRS-1 tyrosine phosphorylation reflects insulin-induced metabolic and mitogenic responses in 3T3-L1 pre-adipocytes Arch Physiol Biochem 109, 52–62 Schurmann, A., Monden, I., Joost, H.G & Keller, K (1992) Subcellular distribution and activity of glucose transporter isoforms GLUT1 and GLUT4 transiently expressed in COS-7 cells Biochim Biophys Acta 1131, 245–252 Reed, B.C & Lane, M.D (1980) Insulin receptor synthesis and turnover in differentiating 3T3-L1 preadipocytes Proc Natl Acad Sci USA 77, 285–289 Simpson, I.A., Yver, D.R., Hissin, P.J., Wardzala, L.J., Karnieli, E., Salans, L.B & Cushman, S.W (1983) Insulin-stimulated translocation of glucose transporters in the isolated rat adipose cells: characterization of subcellular fractions Biochim Biophys Acta 763, 393–407 Robinson, L.J., Pang, S., Harris, D.S., Heuser, J & James, D.E (1992) Translocation of the glucose transporter (GLUT4) to the cell surface in permeabilized 3T3-L1 adipocytes: effects of ATP insulin, and GTP gamma S and localization of GLUT4 to clathrin lattices J Cell Biol 117, 1181–1196 van den Berghe, N., Ouwens, D.M., Maassen, J.A., van Mackelenbergh, M.G., Sips, H.C & Krans, H.M (1994) Activation of the Ras/mitogen-activated protein kinase signaling pathway alone is not sufficient to induce glucose uptake in 3T3-L1 adipocytes Mol Cellular Biol 14, 2372–2377 Burgering, B.M., Medema, R.H., Maassen, J.A., van de Wetering, M.L., van der Eb, A.J., McCormick, F & Bos, J.L (1991) Insulin stimulation of gene expression mediated by p21ras activation EMBO J 10, 1103–1109 Sweeney, G., Somwar, R., Ramlal, T., Volchuk, A., Ueyama, A & Klip, A (1999) An inhibitor of p38 mitogen-activated protein kinase prevents insulin- stimulated glucose transport but not glucose transporter translocation in 3T3-L1 adipocytes and L6 myotubes J Biol Chem 274, 10071–10078 Somwar, R., Perreault, M., Kapur, S., Taha, C., Sweeney, G., Ramlal, T., Kim, D.Y., Keen, J., Cote, C.H., Klip, A & Marette, A (2000) Activation of p38 mitogen-activated protein kinase alpha and beta by insulin and contraction in rat skeletal muscle: potential role in the stimulation of glucose transport Diabetes 49, 1794–1800 BenLevy, R., Leighton, I.A., Doza, Y.N., Attwood, P., Morrice, N., Marshall, C.J & Cohen, P (1995) Identification of novel phosphorylation sites required for activation of MAPKAP kinase2 EMBO J 14, 5920–5930 Tirosh, A., Potashnik, R., Bashan, N & Rudich, A (1999) Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3- L1 adipocytes A putative cellular mechanism for impaired protein kinase B activation and GLUT4 translocation J Biol Chem 274, 10595–10602 Chen, D., Fucini, R.V., Olson, A.L., Hemmings, B.A & Pessin, J.E (1999) Osmotic shock inhibits insulin signaling by maintaining akt protein kinase B in an inactive dephosphorylated state Mol Cellular Biol 19, 4684–4694 Baumann, C.A., Ribon, V., Kanzaki, M., Thurmond, D.C., Mora, S., Shigematsu, S., Bickel, P.E., Pessin, J.E & Saltiel, A.R (2000) CAP defines a second signalling pathway required for insulin-stimulated glucose transport Nature 407, 202–207 Kimura, A., Mora, S., Shigematsu, S., Pessin, J.E & Saltiel, A.R (2002) The insulin receptor catalyzes the tyrosine phosphorylation of caveolin-1 J Biol Chem 277, 30153–30158 Wheeler, T.J (1994) Accelerated net efflux of 3-O-methylglucose from rat adipocytes: a reevaluation Biochim Biophys Acta 1190, 345–354 Ó FEBS 2003 43 Vannucci, S.J., Nishimura, H., Satoh, S., Cushman, S.W., Holman, G.D & Simpson, I.A (1992) Cell surface accessibility of GLUT4 glucose transporters in insulin- stimulated rat adipose cells Modulation by isoprenaline and adenosine Biochem J 288, 325–330 44 Zhang, J.Z., Behrooz, A & Ismail, B.F (1999) Regulation of glucose transport by hypoxia Am J Kidney Dis 34, 189–202 45 Hwang, D.Y & Ismail, B.F (2001) Stimulation of GLUT-1 glucose transporter expression in response to hyperosmolarity Am J Physiol Cell Physiol 281, C1365–C1372 46 Watson, R.T & Pessin, J.E (2001) Intracellular organization of insulin signaling and GLUT4 translocation Recent Prog Horm Res 56, 175–193 47 Clarke, J.F., Young, P.W., Yonezawa, K., Kasuga, M & Holman, G.D (1994) Inhibition of the translocation of GLUT1 and GLUT4 in 3T3-L1 cells by the phosphatidylinositol 3-kinase inhibitor, wortmannin Biochem J 300, 631–635 48 Bosch, R.R., Bazuine, M., Wake, M.M., Span, P.N., Olthaar, A.J., Schurmann, A., Maassen, J.A., Hermus, A.R., Willems, P.H & Sweep, C.G (2003) Inhibition of protein kinase C{beta}II increases glucose uptake in 3T3-L1 adipocytes through elevated expression of GLUT-1 at the plasma membrane Mol Endocrinol 17, 1230–1239 49 Coultrap, S.J., Sun, H., Tenner, T.E Jr & Machu, T.K (1999) Competitive antagonism of the mouse 5-hydroxytryptamine3 receptor by bisindolylmaleimide I, a ÔselectiveÕ protein kinase C inhibitor J Pharmacol Exp Ther 290, 76–82 50 Hers, I., Tavare, J.M & Denton, R.M (1999) The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 318220) are potent inhibitors of glycogen synthase kinase-3 activity FEBS Lett 460, 433–436 51 Cho, H., Youm, J.B., Earm, Y.E & Ho, W.K (2001) Inhibition of acetylcholine-activated K (+) current by chelerythrine and bisindolylmaleimide I in atrial myocytes from mice Eur J Pharmacol 424, 173–178 52 Alessi, D.R (1997) The protein kinase C inhibitors Ro 318220 and GF 109203X are equally potent inhibitors of MAPKAP kinase1beta (Rsk-2) and p70, S6 kinase FEBS Lett 402, 121–123 53 Davies, S.P., Reddy, H., Caivano, M & Cohen, P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors Biochem J 351, 95–105 54 Behrens, M.M., Strasser, U & Choi, D.W (1999) Go 6976 is a potent inhibitor of neurotrophin-receptor intrinsic tyrosine kinase J Neurochem 72, 919–924 55 Martiny-Baron, G., Kazanietz, M.G., Mischak, H., Blumberg, P.M., Kochs, G., Hug, H., Marme, D & Schachtele, C (1993) Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976 J Biol Chem 268, 9194–9197 56 Muller, G., Ayoub, M., Storz, P., Rennecke, J., Fabbro, D & Pfizenmaier, K (1995) PKC zeta is a molecular switch in signal transduction of TNF-alpha, bifunctionally regulated by ceramide and arachidonic acid EMBO J 14, 1961–1969 57 Cheatham, B., Vlahos, C.J., Cheatham, L., Wang, L., Blenis, J & Kahn, C.R (1994) Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70, S6 kinase, DNA synthesis, and glucose transporter translocation Mol Cell Biol 14, 4902– 4911 58 Vlahos, C.J., Matter, W.F., Hui, K.Y & Brown, R.F (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) J Biol Chem 269, 5241–5248 59 Davis, P.D., Elliott, L.H., Harris, W., Hill, C.H., Hurst, S.A., Keech, E., Kumar, M.K., Lawton, G., Nixon, J.S & Wilkinson, S.E (1992) Inhibitors of protein kinase C Substituted bisindolylmaleimides with improved potency and selectivity J Med Chem 35, 994–1001 Ó FEBS 2003 60 Davis, P.D., Hill, C.H., Keech, E., Lawton, G., Nixon, J.S., Sedgwick, A.D., Wadsworth, J., Westmacott, D & Wilkinson, S.E (1989) Potent selective inhibitors of protein kinase C FEBS Lett 259, 61–63 61 Wilkinson, S.E., Parker, P.J & Nixon, J.S (1993) Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C Biochem J 294, 335–337 62 Cuenda, A., Rouse, J., Doza, Y.N., Meier, R., Cohen, P., Gallagher, T.F., Young, P.R & Lee, J.C (1995) SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1 FEBS Lett 364, 229–233 63 Lee, J.C., Laydon, J.T., McDonnell, P.C., Gallagher, T.F., Kumar, S., Green, D., McNulty, D., Blumenthal, M.J., Heys, J.R & Landvatter, S.W (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis Nature 372, 739–746 Arsenite induced glucose-uptake (Eur J Biochem 270) 3903 64 Yaish, P., Gazit, A., Gilon, C & Levitzki, A (1988) Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors Science 242, 933–935 65 Gazit, A., Yaish, P., Gilon, C & Levitzki, A (1989) Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors J Med Chem 32, 2344–2352 66 Yano, H., Nakanishi, S., Kimura, K., Hanai, N., Saitoh, Y., Fukui, Y., Nonomura, Y & Matsuda, Y (1993) Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells J Biol Chem 268, 25846–25856 67 Arcaro, A & Wymann, M.P (1993) Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses Biochem J 296, 297–301  ... insulin- and arsenite- induced pathways to glucose uptake in 3T3-L1 adipocytes Our data suggest some common steps in both arsenite- and insulin-induced glucose uptake: activation of p38 MAPK and. .. contribution of p38- MAPK activity in combination with GLUT4 translocation in insulin- and arsenite- induced glucose uptake at the level of modulating the GLUT4 mediated transport activity Though... glucose uptake as well as MAPKAP-K2 and p38- phosphorylation (Fig 6A,B) In insulin-signalling, p38 MAPK has been implied in enhancing the intrinsic activity of the GLUT4 glucose transporter Thus, SB203580